Combating Inflammatory Diseases with a Novel Therapeutic Approach
We are a clinical stage private company focused on developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin (pGSN). pGSN is a naturally occurring human protein that is at the core of a system to regulate the innate immune response, the first line of defense against both infectious and non-infectious health threats.
>40
PATENTS
20+
COLLABORATORS
$50B
MARKET POTENTIAL
OUR MISSION
To address medical issues previously thought to be out of reach -- preventing the damage caused by excess inflammation without suppressing the immune system.
Plasma Gelsolin Addresses Unmet Medical Needs
Inflammation plays a central role in some of the world’s most challenging diseases. Normal levels of plasma gelsolin (pGSN) are rapidly depleted by diverse inflammatory conditions. Restoring gelsolin levels with BioAegis’ proprietary human recombinant form (rhu-pGSN), helps immune cells fight infection and controls inflammation so it does not spread and cause damage. Rhu-pGSN is a non-antibiotic, host-directed, non-immunosuppressive treatment for inflammation due to both infectious and non-infectious causes.
“Plasma gelsolin is thought be an important anti-inflammatory protein… Low levels correlating with mortality could be an important biomarker for disease and may suggest a potential therapeutic role for exogenously administered gelsolin.”
“Inflammation has hit the big time. Over the past decade, it has become widely accepted that inflammation is a driving force behind chronic diseases that will kill nearly all of us. Cancer. Diabetes and obesity. Alzheimer’s disease. Atherosclerosis. Here, inflammation wears a grim mask, shedding its redeeming features and making sick people sicker…..”
“Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year.”
Creating a Paradigm Shift in Treating Inflammatory Diseases
REGULATES INFLAMMATION
REGULATES INFLAMMATION
ACUTE AND CHRONIC DISEASE APPLICATIONS
ACUTE AND CHRONIC DISEASE APPLICATIONS
KEY COMPONENT OF INNATE IMMUNITY
KEY COMPONENT OF INNATE IMMUNITY
FIGHTS INFECTION/NON IMMUNOSUPPRESSIVE
FIGHTS INFECTION/NON IMMUNOSUPPRESIVE
BENIGN SAFETY PROFILE
BENIGN SAFETY PROFILE
EXTENSIVE IP PORTFOLIO
EXTENSIVE IP PORTFOLIO
A Pipeline Intent on Validating Efficacy for Acute and Chronic Indications
